Boston, MA and Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today will present preclinical data supporting its Allo-GlueTM protein degradation platform for discovery and rational design of small molecule molecular glues at the 5th Annual Targeted Protein Degradation Summit, taking place... Learn more The post Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecu...
